Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

被引：0

作者：

Merryman, Reid W. ^{[1
]}

Belada, David ^{[2
]}

Sureda, Anna ^{[3
]}

Leppa, Sirpa ^{[4
,5
]}

Vermaat, Joost S. P. ^{[6
]}

Holte, Harald ^{[7
,8
]}

Hutchings, Martin ^{[9
]}

Lugtenburg, Pieternella ^{[10
]}

de Vos, Sven ^{[11
]}

Abrisqueta, Pau ^{[12
]}

Nijland, Marcel ^{[13
,14
]}

Christensen, Jacob Haaber ^{[15
]}

Wahlin, Bjorn E. ^{[16
]}

Linton, Kim M. ^{[17
,18
]}

Wang, Liwei ^{[19
]}

Abbas, Aqeel ^{[19
]}

Rana, Ali ^{[19
]}

Quadri, Syed ^{[20
]}

Falchi, Lorenzo ^{[21
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[3] Univ Barcelona, Inst Catala Oncol, Hosp Duran Reynals, IDIBELL, Lhospitalet De Llobregat, Spain

[4] Univ Helsinki, Helsinki, Finland

[5] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland

[6] Leiden Univ, Med Ctr, Leiden, Netherlands

[7] Oslo Univ Hosp, Oslo, Norway

[8] KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[9] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[10] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[11] Ronald Reagan Univ Calif, Los Angeles Med Ctr, Los Angeles, CA USA

[12] Hosp Univ Vall Hebron, Barcelona, Spain

[13] Univ Med Ctr Groningen, Groningen, Netherlands

[14] Univ Groningen, Groningen, Netherlands

[15] Odense Univ Hosp, Odense, Denmark

[16] Karolinska Inst, Stockholm, Sweden

[17] Christie NHS Fdn Trust, Manchester, Lancs, England

[18] Manchester Canc Res Ctr, Manchester, Lancs, England

[19] Genmab, Princeton, NJ USA

[20] AbbVie, N Chicago, IL USA

[21] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

IBCL; bispecific; follicular lymphoma; hematologic malignancy; non-Hodgkin lymphoma; phase I/II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-474

引用

页码：S454 / S454

页数：1

共 50 条

[21] Follicular Lymphoma in a Single Cancer Center and Validation of FLIPI, FLIPI2, PRIMA and POD24 in Non- Caucasian Patients from Peru
Vasquez, Jule F.
Diaz, Alonso
Mendoza, Any S.
Barrionuevo, Carlos
Samanez-Figari, Cesar
BLOOD, 2021, 138
[22] Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
Falchi, Lorenzo
Leppa, Sirpa
Wahlin, Bjorn E.
Nijland, Marcel
Christensen, Jacob Haaber
De Vos, Sven
Holte, Harald
Linton, Kim M.
Abbas, Aqeel
Wang, Liwei
Dinh, Minh
Elliott, Brian
Belada, David
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[23] R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma
McLaughlin, Peter
Neelapu, Sattva
Fanale, Michelle
Rodriguez, Maria
Ayala, Ana
Pro, Barbara
Hagemeister, F. B.
Younes, Anas
Neel, Susan
Fowler, Nathan
Hess, Mark
Kwak, Larry W.
BLOOD, 2008, 112 (11) : 1050 - 1051
[24] Real-World Treatment Patterns and Outcomes of Patients (Pts) with Follicular Lymphoma (FL) Who Experienced Progression of Disease within 24 Months (POD24)
Hamid, Muhammad Saad
Bai, Claire
Perelgut, Chelsea
Yelovich, Helena
Zettler, Christina M.
Fernandes, Laura L.
Belli, Andrew J.
Hansen, Eric
Wang, Ching-Kun
BLOOD, 2023, 142
[25] Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort
Marie Hairing Enemark
Jonas Klejs Hemmingsen
Maja Dam Andersen
Trine Engelbrecht Hybel
Mads Emil Bjørn
Pär Lars Josefsson
Lars Møller Pedersen
Maja Bech Juul
Robert Schou Pedersen
Michael Thorsgaard
Ida Blok Sillesen
Trine Lindhardt Plesner
Stephen Jacques Hamilton-Dutoit
Paw Jensen
Charlotte Madsen
Maja Ludvigsen
Blood Cancer Journal, 14 (1)
[26] Validation of FLIPI1, FLIPI2, PRIMA and POD24 in Patients with Extranodal Follicular Lymphoma: A Cohort from Two Cancer Centers in Peru
Vasquez, Jule F.
Diaz, Alonso
Mendoza, Any S.
Barrionuevo, Carlos
Samanez-Figari, Cesar
BLOOD, 2021, 138
[27] POD24 and Serous Effusion Involvement Impact on Overall Survival in Follicular Lymphoma Attended at the National Cancer Institute in Mexico: A Survey of 370 Patients
Cetina, Gilda
Fernandez, Omar
Aguilar, Isaac
Gutierrez, Olga
Candelaria, Myrna
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S393 - S393
[28] Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)
Wright, George W.
Ramsower, Colleen A.
Cerhan, James R.
Novak, Anne J.
Link, Brian K.
Maurer, Matthew J.
Mwangi, Raphael
Rosenthal, Allison C.
Habermann, Thomas M.
Staudt, Lou
Kridel, Robert
Scott, David W.
Steidl, Christian
Rimsza, Lisa M.
BLOOD, 2022, 140 : 6426 - 6427
[29] External Validation of the FLIPI Risk Score Measured at Initial Diagnosis and POD24 Among Previously Treated Individuals with Progressed Follicular Lymphoma in Alberta, Canada
Owen, Carolyn
Chua, Neil
Boyne, Devon
Joe-Uzuegbu, Ofodile
Shakir, Huma
Gonga, Priyanka
Brenner, Darren
Elia-Pacitti, Julia
Ewara, Emmanuel
Cheung, Winson Y.
BLOOD, 2022, 140 : 8024 - 8025
[30] Epcoritamab with rituximab plus lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7
Lori, Leslie A.
Falchi, Lorenzo
Vermaat, Joost S. P.
Musuraca, Gerardo
Belada, David
Nijland, Marcel
Christensen, Jacob Haaber
Offner, Fritz
Hoehn, Daniela
Marek, Jennifer
Wang, Liwei
Mei, J. P.
Abrisqueta, Pau
Brody, Joshua D.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →